Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Finding Your Motivation: Moves toward a Satisfying Life - 24 Home Rec center Hardware Decisions for Little Spaces
- 3Heartfelt Objections to Visit with Your Adored One
- 4Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- 5Instructions to Pick the Best Course for Your Next Waterway Voyage: Objections, Views, and Social Encounters
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- Must-Sit in front of the Programs from Europe and the US
- Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
- Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- Astronauts beam home Christmas wishes from International Space Station: 'I think we may be orbiting a little higher than Santa' (video)
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- Study casts doubt on potential for life on Jupiter's moon Europa
- Compassion and Association: Building Significant Connections
- Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
